Pharmacist‐Led Cardiac Risk Reduction Model

Taveira, Tracey H.; Wu, Wen‐Chih; Martin, Oanh J.; Schleinitz, Mark D.; Friedmann, Peter D.; Sharma, Satish C.

doi:10.1111/j.1520-037x.2006.05339.x

Cited by 31 publications

(37 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In one study the advertising was targeted to males at high risk of CVD [36]. For a further two studies, participants were referred for CVD screening [24,30]. For the remaining study [32] participant recruitment was not clear.…”

Section: Recruitmentmentioning

confidence: 99%

See 1 more Smart Citation

Pharmacist’s Use of Screening Tools to Estimate Risk of CVD: A Review of the Literature

2014

View full text Add to dashboard Cite

Abstract:To review pharmacist-led screening programmes for estimation of cardiovascular disease (CVD) risk using validated screening tools, studies were identified using a search of the following electronic databases: PubMed, EMBASE, Web of Knowledge and the Cochrane library databases. Each database was searched from inception to December 2011. The search terms used were: "cardiovascular disease", "screening", "risk estimation", "pharmacist" and "pharmacy". Titles, abstracts and full manuscripts were screened to determine eligibility. Inclusion criteria were: (i) Pharmacist-led CVD screening; and (ii) Use of validated screening tool or tools for CVD. From each included study information was collected on the following: Study author; year of publication; setting; inclusion and exclusion criteria; tools used and outcomes measured. Articles were grouped and independently verified to ensure they met with the inclusion criteria. Over 7,000 citations were found. Twenty full-length articles were retrieved for analysis, of which twelve were excluded, as they did not meet the inclusion criteria. The eight remaining articles were included in this literature review. Whilst pharmacists undertake screening in their own practice, this approach will only go so far. To have a population-health impact, pharmacists should be involved in proactive screening in a variety of settings.

show abstract

Section: Recruitmentmentioning

confidence: 99%

“…Pharmacist-led interventions have been shown to be feasible in a number of areas relevant to CVD, such as:  medication use [22];  management of CVD [23,24];  diabetes mellitus (DM) [25,26];  hypertension [27,28]; and  heart failure [29].…”

Section: Introductionmentioning

confidence: 99%

Pharmacist’s Use of Screening Tools to Estimate Risk of CVD: A Review of the Literature

2014

View full text Add to dashboard Cite

show abstract

“…For instance, the majority of pharmacist CV intervention studies rely on physicians to identify patients eligible for the intervention. 2,7,12,14,15,18,19 Although this process can result in the optimization of drug therapy in selected patients, there is no way of knowing whether these individuals represent the entire at-risk population or those at the highest risk. Indeed, the missing link in many chronic disease management programs is the identification of patients who could potentially benefit from the intervention.…”

Section: Original Researchmentioning

confidence: 99%

“…Numerous studies have demonstrated benefits associated with incorporating pharmacists onto primary care teams to facilitate cardiovascular (CV) risk reduction. [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16] However, many such interventions are carried out in small numbers of patients.…”

mentioning

confidence: 99%

Collaborative Cardiovascular Risk Reduction in Primary Care II (CCARP II)

et al. 2013

View full text Add to dashboard Cite

“…We have previously shown the success of this model in the simultaneous control of multiple cardiovascular risk factors in patients with diabetes mellitus or coronary artery disease (CAD). 7,8 Given previous research on the adverse effect of MHCs on cardiovascular risk reduction, we hypothesized that the presence of MHCs would attenuate the treatment efficacy of the CRRC on cardiovascular risk reduction in patients with diabetes. Therefore, we sought to compare the efficacy of the CRRC in the lowering of cardiovascular risk between those with and without MHCs.…”

mentioning

confidence: 99%

Efficacy of a Pharmacist‐Led Cardiovascular Risk Reduction Clinic for Diabetic Patients With and Without Mental Health Conditions

Taveira

Pirraglia

Cohen

et al. 2008

Preventive Cardiology

Self Cite

View full text Add to dashboard Cite

Coexisting mental health conditions (MHCs) attenuate treatment effects in diabetes. A retrospective analysis was performed of a pharmacist‐led cardiovascular risk reduction clinic (CRRC) targeting hypertension, diabetes, hyperlipidemia, and tobacco use in patients with at least one CRRC visit between January 2001 and January 2002. The United Kingdom Prospective Diabetes Study (UKPDS) risk change (after/before CRRC) for those with and without MHCs was compared. Of the 297 with diabetes and complete UKPDS data, 40.7% had at least 1 MHC (22.3% had a severe MHC). Patients with MHCs had a similar number of CRRC visits (4.7±2.6 vs 4.4±2.6) but had a lower baseline UKPDS score (0.31±0.18 vs 0.40±0.20; P=.001) compared with non‐MHC patients. The risk change after CRRC was similar for those with and without MHCs (0.10±0.13 vs 0.10±0.14; P=.82), but patients with MHCs had a longer CRRC enrollment (245±152 vs 205±161 days; P<.03). The efficacy of the CRRC model to reduce cardiovascular risk is not attenuated by a concomitant MHC.

show abstract

Pharmacist‐Led Cardiac Risk Reduction Model

Cited by 31 publications

References 30 publications

Pharmacist’s Use of Screening Tools to Estimate Risk of CVD: A Review of the Literature

Pharmacist’s Use of Screening Tools to Estimate Risk of CVD: A Review of the Literature

Collaborative Cardiovascular Risk Reduction in Primary Care II (CCARP II)

Efficacy of a Pharmacist‐Led Cardiovascular Risk Reduction Clinic for Diabetic Patients With and Without Mental Health Conditions

Contact Info

Product

Resources

About